Enrollment for a pilot study evaluating the effects of Metformin in patients with LFS is now open at The Center for Cancer Research, National Cancer Institute.
- Metformin is currently being studied in over sixty clinical trials of cancers including breast, colon, and uterine cancer, among others. This is the first study in patients with Li-Fraumeni Syndrome investigating the effects of Metformin in this special population.
- Evidence from research studies suggests people with diabetes taking Metformin may have a reduced risk of developing, and dying from, cancer. Metformin has also been widely used in people without diabetes and is well tolerated with minimal side effects.
- The study duration is 20 weeks long and will require some travel to NIH in Bethesda, MD.
If you are interested in learning more about this study, please contact Dr. Farzana Walcott, Lead Associate Investigator at email@example.com or 240-276-7661. Further information can also be found on the NCI Clinical Center webpage and www.clinicaltrials.gov.